13F Pro Quality Score

51.2/100

Rank #1,549 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

61.2/100

Profitability

33.0/100

Balance Sheet

30.7/100

Earnings Quality

88.2/100

Free Cash Flow

34.3/100

Institutional Flow

25.0/100

Revenue Scale

78.7/100

Dilution Risk

33.2/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

BLCO Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for Bausch & Lomb Corp (BLCO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLCO at 51.2/100 on a 32-signal composite quality model, placing it at rank #1,549 of 2,960 stocks — the bottom half of the AI-ranked universe. BLCO scores in the top quartile across earnings quality (88.2), revenue scale (78.7). Areas of concern include institutional flow (25.0) and balance sheet strength (30.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Bausch & Lomb Corp reports quarterly revenue of $1.4B, net income of $-14.0M, an operating margin of 5.9%. Top institutional holders of BLCO by reported 13-F value include ICAHN CARL C, OAKTREE CAPITAL MANAGEMENT, DEUTSCHE BANK AG\, based on the most recent SEC filings. BLCO trades on the NYSE exchange and files with the SEC under CIK 1860742. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLCO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bausch & Lomb Corp directly from SEC EDGAR. Bausch & Lomb Corp's 13F Pro composite quality score has ranged between 42 and 52 since 2026, currently 51.2 — an improving long-term trajectory across 49 quarterly and live scoring snapshots.

Revenue

Q2 2026

$1.4B

Net Income

Q2 2026

$-14.0M

Free Cash Flow

Q2 2026

$82.0M

Operating Margin

Q2 2026

5.9%

ROIC

Q2 2026

2.9%

D/E Ratio

Q2 2026

0.80

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+6.5% YoY
$5.10BFY 2025
FY22 $3.77BFY23 $4.15BFY24 $4.79BFY25 $5.10B

Net Income

-13.6% YoY
$-360.0MFY 2025
FY22 $6.0MFY23 $-260.0MFY24 $-317.0MFY25 $-360.0M

Operating Income

-30.2% YoY
$113.0MFY 2025
FY22 $207.0MFY23 $130.0MFY24 $162.0MFY25 $113.0M

EPS (Diluted)

-13.3% YoY
$-1.02FY 2025
FY22 $0.02FY23 $-0.74FY24 $-0.90FY25 $-1.02

Total Assets

+4.1% YoY
$14.02BFY 2025
FY22 $11.14BFY23 $13.44BFY24 $13.47BFY25 $14.02B

Total Debt

+5.2% YoY
$5.08BFY 2025
FY22 $2.46BFY23 $4.59BFY24 $4.82BFY25 $5.08B

Op. Cash Flow

+22.0% YoY
$283.0MFY 2025
FY22 $345.0MFY23 $-17.0MFY24 $232.0MFY25 $283.0M

Free Cash Flow

-11.9% YoY
$-66.0MFY 2025
FY22 $170.0MFY23 $-198.0MFY24 $-59.0MFY25 $-66.0M

Get alerted when BLCO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Bausch & Lomb Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of BLCO

Companies Similar to BLCO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BHC

Bausch Health Companies Inc.

54
AI score
Similar quality profile · 7 shared holders
NVST

Envista Holdings Corp

54
AI score
Similar quality profile · 4 shared holders
ELAN

Elanco Animal Health Inc

49
AI score
Similar quality profile · 1 shared holders
IART

INTEGRA LIFESCIENCES HOLDINGS CORP

46
AI score
Similar quality profile · 1 shared holders
FTRE

Fortrea Holdings Inc.

43
AI score
Similar quality profile · 2 shared holders
ENOV

Enovis CORP

40
AI score
Similar quality profile · 2 shared holders
EYE

National Vision Holdings, Inc.

52
AI score
Similar quality profile · 1 shared holders
TRUP

TRUPANION, INC.

44
AI score
Similar quality profile · 2 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put BLCO on your watchlist

Track score changes the day Bausch & Lomb Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is BLCO a good stock to buy?

13F Pro's AI-powered analysis of Bausch & Lomb Corp (BLCO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BLCO are available on the BLCO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BLCO is classified as a mid company.

Which hedge funds own BLCO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BLCO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bausch & Lomb Corp's investment landscape.